n.a. (KYTH)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Pfizer's Bid for Allergan May Be Too Good to Turn Down

Pfizer's Bid for Allergan May Be Too Good to Turn Down

With Pfizer's need for tax savings and pipeline products, an offer is expected to hand Allergan shareholders a 30% premium.

KYTHERA(R) Biopharmaceuticals Submits Investigational New Drug Application For KYTH-105 To Treat Androgenetic Alopecia, Or Male Pattern Hair Loss

KYTHERA(R) Biopharmaceuticals Submits Investigational New Drug Application For KYTH-105 To Treat Androgenetic Alopecia, Or Male Pattern Hair Loss

Novel Oral Treatment Could Bring New Option to Large, Unsatisfied Market

KYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application In The European Union For ATX-101 As First-in-Class Treatment For The Reduction Of Submental Fat

KYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application In The European Union For ATX-101 As First-in-Class Treatment For The Reduction Of Submental Fat

Submission Supported by Four Pivotal Phase III Trials Conducted in Europe and North America With More Than 1,500 Patients

KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results And Progress Update

KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results And Progress Update

Company Executing on Commercial Launch of  KYBELLA™ (deoxycholic acid) Injection

Allergan Beats Earnings, Delays Forecast Until Next Quarter

Allergan Beats Earnings, Delays Forecast Until Next Quarter

Drugmaker Allergan withholds guidance for future quarters, following its announcement last week that it's selling its generic drug business to Teva Pharmaceuticals.

Allergan Beats Estimates, Company to Update Guidance Next Quarter

Allergan Beats Estimates, Company to Update Guidance Next Quarter

Drugmaker Allergan is putting off issuing guidance for future quarters following the company's announcement last week that it's selling its generic drug business to Teva Pharmaceuticals.

What to Watch Thursday -- Trump, Bush, Allergan Earnings, Jobless Claims

What to Watch Thursday -- Trump, Bush, Allergan Earnings, Jobless Claims

On Thursday August 6, TheStreet will be covering the first Republican Presidential debates, earnings from drug manufacturer Allergan and media company Viacom, and jobless claims.

KYTHERA Biopharmaceuticals Announces Health Canada Authorization Of BELKYRA(TM), A Submental Contouring Injectable Drug(i)

KYTHERA Biopharmaceuticals Announces Health Canada Authorization Of BELKYRA(TM), A Submental Contouring Injectable Drug(i)

Recently Launched as KYBELLA(TM) in the U.S., BELKYRA(TM) Deoxycholic Acid Injection Improves Appearance and Profile of Moderate to Severe Submental Fullness or "Double Chin"

KYTHERA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of KYTHERA Biopharmaceuticals, Inc. (KYTH) Over The Proposed Sale Of The Company To Allergan Plc.

KYTHERA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of KYTHERA Biopharmaceuticals, Inc. (KYTH) Over The Proposed Sale Of The Company To Allergan Plc.

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of KYTHERA Biopharmaceuticals, Inc.

Short Interest In Kythera Biopharmaceuticals Moves 68.6% Lower

Short Interest In Kythera Biopharmaceuticals Moves 68.6% Lower

The most recent short interest data has been released by the NASDAQ for the 06/30/2015 settlement date, which shows a 4,141,874 share decrease in total short interest for Kythera Biopharmaceuticals, Inc. , to 1,897,697, a decrease of 68.58% since 06/15/2015.

10 Best Biotech Stocks in the NASDAQ

10 Best Biotech Stocks in the NASDAQ

The biotech sector has been one of the fastest growing sectors through June 30, 2015. Here are the 10 best biotech stocks this year.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation Of The Board Of Directors Of Kythera Biopharmaceuticals, Inc.

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation Of The Board Of Directors Of Kythera Biopharmaceuticals, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Kythera Biopharmaceuticals, Inc.

KYTH INVESTOR ALERT: The Law Offices Of Vincent Wong Launches An Investigation Of The Board Of Directors Of KYTHERA Biopharmaceuticals, Inc. Concerning The Sale Of The Company To Allergan Plc

KYTH INVESTOR ALERT: The Law Offices Of Vincent Wong Launches An Investigation Of The Board Of Directors Of KYTHERA Biopharmaceuticals, Inc. Concerning The Sale Of The Company To Allergan Plc

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of KYTHERA Biopharmaceuticals, Inc.

EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Kythera Biopharmaceuticals Inc. Concerning Its Proposed Sale To Allergan Plc - KYTH

EQUITY ALERT: The Rosen Law Firm Announces Investigation Of Kythera Biopharmaceuticals Inc. Concerning Its Proposed Sale To Allergan Plc - KYTH

The Rosen Law Firm, a global investor rights law firm, announces that it is investigating the Board of Directors of Kythera Biopharmaceuticals Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of KYTHERA Biopharmaceuticals, Inc. Of Commencement Of An Investigation Regarding The Fairness Of The Sale Of The Company To Allergan Plc

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of KYTHERA Biopharmaceuticals, Inc. Of Commencement Of An Investigation Regarding The Fairness Of The Sale Of The Company To Allergan Plc

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased KYTHERA Biopharmaceuticals, Inc.

Jim Cramer's Top Takeaways: BioMarin, Radius Health, Allergan, Diageo, Wayfair

Jim Cramer's Top Takeaways: BioMarin, Radius Health, Allergan, Diageo, Wayfair

Cramer says BioMarin, Radius Health and Allergan are winners but stay away from Diageo.

Jim Cramer's 'Mad Money' Recap: Here's Why We Had a Rally Today

Jim Cramer's 'Mad Money' Recap: Here's Why We Had a Rally Today

The Federal Reserve statement, Greece, selling the dollar and investor confidence all had a hand, Cramer says.

Finkelstein Thompson LLP Investigates Potentially Unfair Buyout Of KYTHERA Biopharmaceuticals, Inc.

Finkelstein Thompson LLP Investigates Potentially Unfair Buyout Of KYTHERA Biopharmaceuticals, Inc.

Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of KYTHERA Biopharmaceuticals, Inc.

Jim Cramer's Top Takeaways: Palo Alto Networks, Tesla, Ambarella, Allergan, Wingstop, Alkermes

Jim Cramer's Top Takeaways: Palo Alto Networks, Tesla, Ambarella, Allergan, Wingstop, Alkermes

Cramer says Allergan dominates treatments for your face with its buy of Kythera Biopharmaceuticals but it's time to ring the register on newly public Wingstop.

Market News: Tripadvisor, Kythera Biopharmaceuticals, Qihoo 360

Market News: Tripadvisor, Kythera Biopharmaceuticals, Qihoo 360

The stock markets in the United States gained after the Federal Reserve indicated any interest rate hike would be gradual as Chairperson Janet Yellen wants to see more definitive evidence of economic ...

Stocks Climb as Fed Meeting Suggests 2015 Hikes

Stocks Climb as Fed Meeting Suggests 2015 Hikes

Stocks closed in the green on Wednesday, but not without something of a struggle as markets bounced around in narrow range-bound trading.

5 Stocks on Traders' Radars -- and What You Should Do With Them

5 Stocks on Traders' Radars -- and What You Should Do With Them

Here's a look at how to trade some of the most active stocks on Wall Street right now.

Stocks Recover; Yellen Sees Residual Weakness in Labor Market

Stocks Recover; Yellen Sees Residual Weakness in Labor Market

Stocks recover after the Federal Reserve keeps rates unchanged at its meeting on Wednesday.

Allergan Broadens Its Aesthetics Business With Its $2.1B Kythera Acquisition

Allergan Broadens Its Aesthetics Business With Its $2.1B Kythera Acquisition

Allergan plc, which is known for its Botox product, said June 17 it is acquiring Kythera Biopharmaceuticals Inc. in a cash and stock deal valued at approximately $2.1 billion.

Synergy Jumps on Positive Results; Stocks Climb Ahead of Fed

Synergy Jumps on Positive Results; Stocks Climb Ahead of Fed

Synergy Pharmaceuticals (SGYP) jumped in midday trading Wednesday after announcing its experimental drug for chronic constipation had achieved its primary goal.